TRIM5

Across TCGA pan-cancer cohorts, TRIM5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIM5 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIM5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where TRIM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.267	0.619	.002	25	view →
UCEC	OS	Median	III,IV	0.312	1.000	.003	20	view →
LUAD	OS	Quartile	All	0.872	0.612	.011	19	view →
CCRCC	OS	Median	II,III,IV	0.327	0.917	.015	11	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	8	view →
LSCC	OS	Tertile	II,III,IV	0.756	0.958	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIM5–PDAC (OS)

Open the PDAC breakdown →